Financhill
Sell
30

ICUI Quote, Financials, Valuation and Earnings

Last price:
$134.92
Seasonality move :
-1.03%
Day range:
$129.72 - $135.62
52-week range:
$101.44 - $196.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.36x
P/B ratio:
1.66x
Volume:
384.2K
Avg. volume:
279.9K
1-year change:
32.91%
Market cap:
$3.3B
Revenue:
$2.4B
EPS (TTM):
-$3.83

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ICUI
ICU Medical
$574.2M $1.28 -8.91% 316.67% $186.20
ALDX
Aldeyra Therapeutics
-$666.7K -$0.24 -- -25% $8.29
MASI
Masimo
$367.8M $1.21 -25.72% 321.55% $182.07
MMSI
Merit Medical Systems
$352.6M $0.75 10.2% 39.06% $108.55
OGN
Organon &
$1.5B $0.89 -3.44% 24.83% $14.00
RGEN
Repligen
$163.8M $0.35 9.93% 286.84% $183.13
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ICUI
ICU Medical
$134.43 $186.20 $3.3B -- $0.00 0% 1.36x
ALDX
Aldeyra Therapeutics
$2.28 $8.29 $136.6M -- $0.00 0% --
MASI
Masimo
$156.97 $182.07 $8.5B 116.80x $0.00 0% 4.31x
MMSI
Merit Medical Systems
$94.82 $108.55 $5.6B 46.48x $0.00 0% 4.10x
OGN
Organon &
$9.54 $14.00 $2.5B 3.31x $0.02 9.02% 0.39x
RGEN
Repligen
$122.32 $183.13 $6.9B 633.44x $0.00 0% 10.58x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ICUI
ICU Medical
43.6% 1.698 44.96% 0.90x
ALDX
Aldeyra Therapeutics
-- 0.040 -- --
MASI
Masimo
40.75% 1.411 7.21% 0.87x
MMSI
Merit Medical Systems
33.84% 1.291 11.7% 3.11x
OGN
Organon &
94.29% 0.321 233.18% 0.77x
RGEN
Repligen
21.06% 1.369 7.41% 5.56x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ICUI
ICU Medical
$210.1M $29.6M -2.6% -4.64% 2.37% $34.5M
ALDX
Aldeyra Therapeutics
-- -$10.4M -- -- -- -$12.5M
MASI
Masimo
$234M $80.7M -24.62% -39.91% 20.75% $27M
MMSI
Merit Medical Systems
$172M $42.1M 5.84% 9.19% 12.53% $19.1M
OGN
Organon &
$841M $325M 8.21% 220.72% 14.87% -$22M
RGEN
Repligen
$90.8M $6.6M -0.91% -1.16% 7.8% $10.6M

ICU Medical vs. Competitors

  • Which has Higher Returns ICUI or ALDX?

    Aldeyra Therapeutics has a net margin of -2.56% compared to ICU Medical's net margin of --. ICU Medical's return on equity of -4.64% beat Aldeyra Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ICUI
    ICU Medical
    34.75% -$0.63 $3.5B
    ALDX
    Aldeyra Therapeutics
    -- -$0.17 --
  • What do Analysts Say About ICUI or ALDX?

    ICU Medical has a consensus price target of $186.20, signalling upside risk potential of 38.51%. On the other hand Aldeyra Therapeutics has an analysts' consensus of $8.29 which suggests that it could grow by 263.41%. Given that Aldeyra Therapeutics has higher upside potential than ICU Medical, analysts believe Aldeyra Therapeutics is more attractive than ICU Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    ICUI
    ICU Medical
    3 1 0
    ALDX
    Aldeyra Therapeutics
    5 0 0
  • Is ICUI or ALDX More Risky?

    ICU Medical has a beta of 0.870, which suggesting that the stock is 12.976% less volatile than S&P 500. In comparison Aldeyra Therapeutics has a beta of 0.917, suggesting its less volatile than the S&P 500 by 8.339%.

  • Which is a Better Dividend Stock ICUI or ALDX?

    ICU Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical pays -- of its earnings as a dividend. Aldeyra Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ICUI or ALDX?

    ICU Medical quarterly revenues are $604.7M, which are larger than Aldeyra Therapeutics quarterly revenues of --. ICU Medical's net income of -$15.5M is lower than Aldeyra Therapeutics's net income of -$9.9M. Notably, ICU Medical's price-to-earnings ratio is -- while Aldeyra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical is 1.36x versus -- for Aldeyra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ICUI
    ICU Medical
    1.36x -- $604.7M -$15.5M
    ALDX
    Aldeyra Therapeutics
    -- -- -- -$9.9M
  • Which has Higher Returns ICUI or MASI?

    Masimo has a net margin of -2.56% compared to ICU Medical's net margin of -45.89%. ICU Medical's return on equity of -4.64% beat Masimo's return on equity of -39.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    ICUI
    ICU Medical
    34.75% -$0.63 $3.5B
    MASI
    Masimo
    62.9% -$3.17 $1.6B
  • What do Analysts Say About ICUI or MASI?

    ICU Medical has a consensus price target of $186.20, signalling upside risk potential of 38.51%. On the other hand Masimo has an analysts' consensus of $182.07 which suggests that it could grow by 15.99%. Given that ICU Medical has higher upside potential than Masimo, analysts believe ICU Medical is more attractive than Masimo.

    Company Buy Ratings Hold Ratings Sell Ratings
    ICUI
    ICU Medical
    3 1 0
    MASI
    Masimo
    4 3 0
  • Is ICUI or MASI More Risky?

    ICU Medical has a beta of 0.870, which suggesting that the stock is 12.976% less volatile than S&P 500. In comparison Masimo has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.855%.

  • Which is a Better Dividend Stock ICUI or MASI?

    ICU Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ICUI or MASI?

    ICU Medical quarterly revenues are $604.7M, which are larger than Masimo quarterly revenues of $372M. ICU Medical's net income of -$15.5M is higher than Masimo's net income of -$170.7M. Notably, ICU Medical's price-to-earnings ratio is -- while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical is 1.36x versus 4.31x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ICUI
    ICU Medical
    1.36x -- $604.7M -$15.5M
    MASI
    Masimo
    4.31x 116.80x $372M -$170.7M
  • Which has Higher Returns ICUI or MMSI?

    Merit Medical Systems has a net margin of -2.56% compared to ICU Medical's net margin of 8.48%. ICU Medical's return on equity of -4.64% beat Merit Medical Systems's return on equity of 9.19%.

    Company Gross Margin Earnings Per Share Invested Capital
    ICUI
    ICU Medical
    34.75% -$0.63 $3.5B
    MMSI
    Merit Medical Systems
    48.41% $0.49 $2.2B
  • What do Analysts Say About ICUI or MMSI?

    ICU Medical has a consensus price target of $186.20, signalling upside risk potential of 38.51%. On the other hand Merit Medical Systems has an analysts' consensus of $108.55 which suggests that it could grow by 14.48%. Given that ICU Medical has higher upside potential than Merit Medical Systems, analysts believe ICU Medical is more attractive than Merit Medical Systems.

    Company Buy Ratings Hold Ratings Sell Ratings
    ICUI
    ICU Medical
    3 1 0
    MMSI
    Merit Medical Systems
    5 1 0
  • Is ICUI or MMSI More Risky?

    ICU Medical has a beta of 0.870, which suggesting that the stock is 12.976% less volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.696, suggesting its less volatile than the S&P 500 by 30.439%.

  • Which is a Better Dividend Stock ICUI or MMSI?

    ICU Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical pays -- of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ICUI or MMSI?

    ICU Medical quarterly revenues are $604.7M, which are larger than Merit Medical Systems quarterly revenues of $355.4M. ICU Medical's net income of -$15.5M is lower than Merit Medical Systems's net income of $30.1M. Notably, ICU Medical's price-to-earnings ratio is -- while Merit Medical Systems's PE ratio is 46.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical is 1.36x versus 4.10x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ICUI
    ICU Medical
    1.36x -- $604.7M -$15.5M
    MMSI
    Merit Medical Systems
    4.10x 46.48x $355.4M $30.1M
  • Which has Higher Returns ICUI or OGN?

    Organon & has a net margin of -2.56% compared to ICU Medical's net margin of 5.75%. ICU Medical's return on equity of -4.64% beat Organon &'s return on equity of 220.72%.

    Company Gross Margin Earnings Per Share Invested Capital
    ICUI
    ICU Medical
    34.75% -$0.63 $3.5B
    OGN
    Organon &
    55.59% $0.33 $9.5B
  • What do Analysts Say About ICUI or OGN?

    ICU Medical has a consensus price target of $186.20, signalling upside risk potential of 38.51%. On the other hand Organon & has an analysts' consensus of $14.00 which suggests that it could grow by 46.75%. Given that Organon & has higher upside potential than ICU Medical, analysts believe Organon & is more attractive than ICU Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    ICUI
    ICU Medical
    3 1 0
    OGN
    Organon &
    0 3 0
  • Is ICUI or OGN More Risky?

    ICU Medical has a beta of 0.870, which suggesting that the stock is 12.976% less volatile than S&P 500. In comparison Organon & has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ICUI or OGN?

    ICU Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Organon & offers a yield of 9.02% to investors and pays a quarterly dividend of $0.02 per share. ICU Medical pays -- of its earnings as a dividend. Organon & pays out 34.38% of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ICUI or OGN?

    ICU Medical quarterly revenues are $604.7M, which are smaller than Organon & quarterly revenues of $1.5B. ICU Medical's net income of -$15.5M is lower than Organon &'s net income of $87M. Notably, ICU Medical's price-to-earnings ratio is -- while Organon &'s PE ratio is 3.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical is 1.36x versus 0.39x for Organon &. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ICUI
    ICU Medical
    1.36x -- $604.7M -$15.5M
    OGN
    Organon &
    0.39x 3.31x $1.5B $87M
  • Which has Higher Returns ICUI or RGEN?

    Repligen has a net margin of -2.56% compared to ICU Medical's net margin of 3.45%. ICU Medical's return on equity of -4.64% beat Repligen's return on equity of -1.16%.

    Company Gross Margin Earnings Per Share Invested Capital
    ICUI
    ICU Medical
    34.75% -$0.63 $3.5B
    RGEN
    Repligen
    53.65% $0.10 $2.5B
  • What do Analysts Say About ICUI or RGEN?

    ICU Medical has a consensus price target of $186.20, signalling upside risk potential of 38.51%. On the other hand Repligen has an analysts' consensus of $183.13 which suggests that it could grow by 49.71%. Given that Repligen has higher upside potential than ICU Medical, analysts believe Repligen is more attractive than ICU Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    ICUI
    ICU Medical
    3 1 0
    RGEN
    Repligen
    10 5 0
  • Is ICUI or RGEN More Risky?

    ICU Medical has a beta of 0.870, which suggesting that the stock is 12.976% less volatile than S&P 500. In comparison Repligen has a beta of 1.207, suggesting its more volatile than the S&P 500 by 20.699%.

  • Which is a Better Dividend Stock ICUI or RGEN?

    ICU Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical pays -- of its earnings as a dividend. Repligen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ICUI or RGEN?

    ICU Medical quarterly revenues are $604.7M, which are larger than Repligen quarterly revenues of $169.2M. ICU Medical's net income of -$15.5M is lower than Repligen's net income of $5.8M. Notably, ICU Medical's price-to-earnings ratio is -- while Repligen's PE ratio is 633.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical is 1.36x versus 10.58x for Repligen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ICUI
    ICU Medical
    1.36x -- $604.7M -$15.5M
    RGEN
    Repligen
    10.58x 633.44x $169.2M $5.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Dell Stock Be in 5 Years?
Where Will Dell Stock Be in 5 Years?

So you’re looking at Dell (NASDAQ: DELL) and wondering, “Is…

Where Will Cameco Stock Be in 5 Years?
Where Will Cameco Stock Be in 5 Years?

Cameco (NYSE: CCJ) isn’t exactly the kind of stock you…

Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth
Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth

Microsoft (NASDAQ:MSFT) has been among the top growth stocks of…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
70
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 47x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
84
SBET alert for May 30

SharpLink Gaming [SBET] is down 3.17% over the past day.

Buy
55
RGC alert for May 30

Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.

Buy
73
CTEV alert for May 30

Claritev [CTEV] is up 7.82% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock